Outlook Therapeutics, Inc. has officially moved forward with resubmitting a Biologics License Application (BLA) for ONS-5010 (bevacizumb-vikg), its investigational wet age-related macular degeneration (AMD) candidate.
The news comes just days (literally two days) after the company secured a win in its appeal to the FDA over its third rejection from the federal agency.
That’s quite the turnaround … let’s start with some background.
Click here for details on:
- This intravitreally (IVT)-administered investigational asset.
- Its clinical trial outcomes
- Its three prior BLA submission attempts (rejections included)
And could you explain what led to that appeal to the FDA?
That would be the completion of a Federal Dispute Resolution (FDR) process, which Outlook pursued after the FDA issued a complete response letter (CRL)—its third, to be exact—in December 2026 over the wet AMD asset’s latest BLA submission.
To refresh: This rundown explains the basics of what an FDR process involves.
Did the company share how it secured its regulatory win?
Indeed. According to Outlook, it submitted a comprehensive presentation of clinical, functional, and pharmacodynamic data (plus safety findings)—with specific datasets from a few key trials (think: NORSE TWO and NORSE EIGHT, among others).
- See here for those details (and clinical data).
Tell me more about this FDA decision.
To be more specific: The federal agency’s Office of New Drugs concluded that “substantial evidence of effectiveness” was established for LYTENVAVA’s wet AMD.
As a result (and more importantly): “Additional trials are not required.”
Hence … this new submission?
Precisely. As we reported last week, Outlook’s (fourth) BLA submission is categorized as a Class 1 resubmission. See here for what that means.
And regarding the submission package: The FDA’s Division of Ophthalmology and Office of Specialty Medicine is currently working with Outlook to reach an agreement on final product labeling.
So, has a PDUFA date been assigned yet?
That would be jumping the gun … the FDA first has 60 days to accept (or reject) this latest submission.
If accepted, only then will a Prescription Drug User Fee Act (PDUFA) date be assigned.
Gotcha. Last question: Tell me about the big-picture potential.
As we’ve noted previously: LYTENAVA could become the first on-label bevacizumab product specifically formulated for IVT retinal use in the United States.
See here for exclusivity details that would also come with this.